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Abstract
Introduction: Cigarette smoking, various metabolic and lipid-related factors and hypertension are 
well-recognized cardiovascular disease (CVD) risk factors. Since smoking affects many of these 
factors, use of a single imprecise smoking metric, for example, ever or never smoked, may allow 
residual confounding and explain inconsistencies in current assessments of interactions.
Methods: Using a comprehensive model in pack-years and cigarettes/day for the complex smok-
ing-related relative risk (RR) of CVD to reduce residual confounding, we evaluated interactions 
with non-tobacco risk factors, including additive (non-synergistic) and multiplicative (synergistic) 
forms. Data were from the prospective Atherosclerosis Risk in Communities (ARIC) Study from 
four areas of the United States recruited in 1987–1989 with follow-up through 2008. Analyses 
included 14 127 participants, 207 693 person-years and 2857 CVD events.
Results: Analyses revealed distinct interactions with smoking: including statistical consistency 
with additive (body mass index [BMI], waist to hip ratio [WHR], diabetes mellitus [DM], glucose, 
insulin, high density lipoproteins [HDL] and HDL(2)); and multiplicative (hypertension, total cho-
lesterol [TC], low density lipoproteins [LDLs], apolipoprotein B [apoB], TC to HDL ratio and HDL(3)) 
associations, as well as indeterminate (apolipoprotein A-I [apoA-I] and triglycerides) associations.
Conclusions: The forms of the interactions were revealing but require confirmation. Improved under-
standing of joint associations may help clarify the public health burden of smoking for CVD, links between 
etiologic factors and biological mechanisms, and the consequences of joint exposures, whereby syner-
gistic associations highlight joint effects and non-synergistic associations suggest distinct contributions.
Implications: Joint associations for cigarette smoking and non-tobacco risk factors were distinct, reveal-
ing synergistic/multiplicative (hypertension, TC, LDL, apoB, TC/HDL, HDL(3)), non-synergistic/additive 
(BMI, WHR, DM, glucose, insulin, HDL, HDL(2)) and indeterminate (apoA-I and TRIG) associations. If 
confirmed, these results may help better define the public health burden of smoking on CVD risk and 
identify links between etiologic factors and biologic mechanisms, where synergistic associations high-
light joint impacts and non-synergistic associations suggest distinct contributions from each factor.
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Introduction
Cigarette smoking and various non-tobacco factors (eg, metabolic 
and lipid-related factors and hypertension) are well-recognized risk 
factors for cardiovascular disease (CVD).1–4 Evaluations of joint 
relative risks (RRs) for cigarette consumption and non-tobacco 
factors are complicated since smoking affects many of these fac-
tors.5–14 Previous analyses of interactions have computed RRs for 
non-tobacco factors by smoking status or broad categories of ciga-
rettes/day.15–32 Since a single imprecise metric does not fully charac-
terize smoking-related risks, residual confounding from incomplete 
account of smoking may have influenced previous assessments of 
interaction.
In contrast, use of a comprehensive model that more com-
pletely characterizes smoking-related CVD risks reduces residual 
confounding and thus enables a more complete description of the 
joint association between smoking exposure and non-tobacco risk 
factors. In particular, an enhanced characterization of smoking 
risks improves the ability to assess synergistic and non-synergis-
tic associations, which may help clarify the public health burden 
of smoking and links between etiologic factors and biological 
mechanisms.
Investigators often cross-tabulate RRs for two factors with 
never-smokers as the referent group to improve characterization 
of smoking-related disease risk; however, the choice is usually cig-
arettes/day and duration of smoking, which leads to problems of 
interpretation.33–35 For example, in a simple log-linear RR model 
with cigarettes/day and duration, the cigarettes/day parameter rep-
resents a unit increase in the ln(RR) per cigarette/day with dura-
tion held fixed. Since duration is fixed, RRs for increasing cigarettes/
day necessarily embed increasing total pack-years. Consequently, for 
30 years of smoking, a comparison of RRs at 20 and 30 cigarettes/
day reflects not only different smoking rates but also different total 
exposures, that is, 30 and 45 pack-years, respectively, or 110 000 
(≈15 × 20 × 365.25) additional cigarettes. Hence, the cigarettes/day 
and duration parameters are not interpretable as distinct, unrelated 
effects.
In contrast, we analyze RRs for pack-years and cigarettes/day, 
so that smoking rate represents a modifier of RR trends with pack-
years. Using data from the Atherosclerosis Risk in Communities 
(ARIC) Study, we developed a comprehensive two-parameter model 
in pack-years and cigarettes/day that describes smoking-related RRs 
of CVD36 (Supplementary Material).
This approach allows a more direct interpretation of results, as 
the differential in the RRs at a fixed pack-years when delivered at 
lower smoking rates for longer durations or higher rates for shorter 
durations, or alternatively the cigarettes/day effect defines the rela-
tive influence of exposure accrual on the RR at a given pack-years. 
This approach reinterprets RRs for cigarettes/day as a “delivery 
rate effect.” In the current paper, we use this model for the complex 
smoking-related risks of CVD and evaluate the joint interaction of 
smoking with selected non-tobacco risk factors.
A non-synergistic relationship for two factors occurs when the 
excess disease rate for exposure to both factors compared to the 
disease rate in the absence of both factors equals the sum of the 
individual excess rates at the referent level of the other.37,38 This is 
often termed an additive relationship. In contrast, when the excess 
disease rate with both exposures is greater than (less than) the sum 
of the excess for each factor the relationship is termed synergistic 
(antagonistic). For RRs, a joint excess RR (ERR) that equals the 
additive ERR of each factor defines a non-synergistic (additive) 
relationship, while any joint ERR that is greater than (less than) 
the individual additive ERRs describes a synergistic (antagonistic) 
relationship. Since the precise extent of any departure from addi-
tivity is unspecified, a multiplicative association, in which the joint 
RR equals the product of factor-specific RRs, represents one type 
of synergistic relationship. Additive and multiplicative associations 
represent signpost models on a continuum, which ranges from sub-
additive to supra-multiplicative. A synergistic association highlights 
the potential importance of both factors, while a non-synergistic 
association suggests distinct risk contributions.
Material and Methods
Study Design
The ARIC Study is an ongoing cohort study conducted in four areas 
of the United States: Forsyth County, North Carolina; Jackson, 
Mississippi; Washington County, Maryland; and the northwest 
suburbs of Minneapolis, Minnesota. Enrollment occurred between 
1987 and 1989 using a probability-based sample of adults aged 
45–64 years. See references for details.39–42 Study personnel collected 
data from clinical examinations and personal interviews at enroll-
ment and at three clinic visits: 1990–1992 (visit 2), 1993–1995 (visit 
3) and 1996–1998 (visit 4). Annual telephone calls solicited informa-
tion from participants or surrogates on vital status, hospital visits 
and other factors.
For current analyses, the outcome of interest is CVD, which 
encompasses coronary heart disease (CHD) and stroke.42 We ascer-
tained outcome information through annual telephone interviews, 
hospital discharge records in study areas and death certificates. 
Outcomes were validated by examination of hospital records, death 
certificates and, when available, autopsy records and classified 
according to ARIC Study criteria.42 A validated, definite or probable 
hospitalized myocardial infarction, a definite CHD death, an unrec-
ognized myocardial infarction defined by electrocardiographic read-
ing, or coronary revascularization defined CHD.41 A  stroke event 
comprised a validated, definite or probable hospitalized ischemic or 
hemorrhagic stroke.
Enrollment questionnaires and clinic visits provided information 
on smoking status and cigarettes/day, while annual telephone con-
tacts provided information on smoking status only. For cigarettes/
day, we used enrollment information, since time-dependent data 
were limited and follow-up was short relative to total smoking dura-
tion. At enrollment there were 26.3% current smokers, half of whom 
subsequently ceased smoking. Among continuing smokers, smoking 
rate changed minimally with follow-up. Clinic questionnaires and 
annual telephone contacts yielded time-dependent information on 
smoking status, which enabled time-dependent calculations of smok-
ing duration, pack-years and time since cessation.
We conducted a 12-hour fasting blood collection and measured 
glucose and plasma total cholesterol (TC) by standard enzymatic 
methods at a centralized laboratory facility using a common pro-
tocol. We designated diabetes occurrence as a self-reported his-
tory of, or treatment for, diabetes, a fasting glucose level ≥126 mg/
dL (7.0  mmol/L), or a random blood glucose level ≥200 mg/dL 
(11.1  mmol/L).42 We assayed low density lipoprotein (LDL), TC, 
triglycerides (TRIG), high density lipoprotein (HDL), HDL sub-frac-
tions HDL(2), HDL(3), apolipoprotein A-I (apoA-I) and apolipopro-
tein B (apoB) as described previously.22,43 We defined hypertension 
as blood pressure >140/90 mm Hg and/or use of antihypertensive 
medication.42
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We followed participants who were CVD free at enrollment 
through the earliest date of CVD diagnosis, death, loss to follow-
up or December 31, 2008. The initial dataset included 14 878 sub-
jects and 3603 CVD events, from which we excluded 751 (5.0%) 
participants who were missing enrollment data, including 212 
CVD (5.9%) events. Missing information arose primarily from 
smoking (247 subjects and 59 CVD cases), lipid measurements 
(228 subjects and 64 cases), body mass index (BMI) and diabe-
tes diagnosis (43 subjects and 15 cases), alcohol use (78 subjects 
and 24 cases) and other variables (155 subjects and 50 cases). 
We limited analyses to white and African American participants, 
omitting 42 participants of other racial or ethnic groups (eight 
CVD events) and leaving 14 085 participants, 3383 CVD events 
and 231 293 person-years. Since there were baseline data on meta-
bolic and lipid variables on nearly all participants and since the 
study did not ascertain all variables at every clinic visit, we used 
enrollment values for non-tobacco variables. Because smoking 
status may affect many of these factors, we censored follow-up 
when a participant changed baseline smoking status. For smok-
ing variables, we calculated time-dependent cessation and dura-
tion of smoking, which allowed time-dependent pack-years. The 
censoring excluded person-time and CVD events that occurred 
after a post-enrollment change in smoking status. The final dataset 
included 2857 CVD events and 207 686 person-years.
The institutional review board of each participating university 
approved the study protocol; including the Coordinating Center, 
University of North Carolina at Chapel Hill, Public Health-Nursing 
Institutional Review Board (IRB); Forsyth County field center, Wake 
Forest University IRB; Jackson field center, University of Mississippi 
IRB; Minnesota field center, University of Minnesota IRB: Human 
Subjects Protection Program; and Washington County field center, 
Johns Hopkins Bloomberg School of Public Health IRB. The Special 
Studies IRB of the National Cancer Institute approved the current 
protocol and transfer of data to the Division of Cancer Epidemiology 
and Genetics. All subjects gave written informed consent.
Data Structure
We fitted Poisson regression models to data cross-classified into a 
multi-way table defined by attained age (<54, 54–55, …, 78–79, 
≥80), calendar period (<1990, 1990–1994, 1995–1999, 2000–2004, 
2005–2009), birth year (<1930, 1930–1934, 1935–1939, ≥1940), 
study site, sex, race (white, African American), BMI (<25.0, 25.0–
29.9, 30.0–34.9, ≥35.0 kg/m2), alcohol consumption in gm-ethanol/
wk (<40, 40–107, ≥108), hypertensive status, diabetes mellitus sta-
tus (DM), TC (<5.2, 5.2–6.1, ≥6.2 mmol/L), ever use of cigars/pipes, 
education (<12 years, high/vocational school, college/graduate/pro-
fessional school), cigarettes/day (0, 1–4, 5–9, …, 45–49, ≥50), pack-
years (0, 1–9, 10–19, 20–24, …, 55–59, ≥60) and years since last 
smoked (<1, 1–4, 5–9, 10–19, ≥20). Additional variables included 
waist to hip ratio (WHR), LDL, TRIG, apoB, apoA-I, glucose, insu-
lin, HDL, HDL(2), HDL(3) and TC/HDL. For each cell of the multi-
way table, we tabulated person-years, CVD events and person-years 
weighted means for continuous variables.
RR Models
Our goal was to characterize the joint RR of smoking and risk factor 
(x). We specified the RR of smoking as RR(d,n,y) using pack-years 
(d), cigarettes/day (n) and years since last smoked (y), and the RR for 
x as RR(x). Initially, we assumed that x was categorical with F levels.
In a non-synergistic or additive association, the ERR for smoking 
and x add, that is,
 RR RR RRd n y x d n y x, , , , ,( ) − = ( ) −{ } + ( ) −{ }1 1 1  
or alternatively
  
RR RR RRd n y x d n y x, , , , ,( ) = ( ) + ( ) − 1  (1)
Here, the contribution to the disease rate from one factor does not 
impact the contribution of other factor. In a multiplicative relation-
ship, the individual RRs multiple, that is,
  RR RR RRd n y x d n y x, , , , ,( ) = ( ) × ( )  (2)
The contribution to the disease rate of one factor depends on the 
level of the other factor, reflecting a type of synergistic association.
Characterization of a joint relationship, for example, multiplica-
tive or additive, is distinct from patterns of RRs for the individual 
factors.44 Typically, the multiplicative and additive models include 
the same numbers of parameters and thus are not nested. We utilized 
two approaches to embed these forms within a larger class of mod-
els. We first applied a geometric mean mixture:
RR RR RR RR RR( , , , ) , , , , ( )
(
d n y x d n y x d n y x= × × + −( ) ( )  ( )  −λ λ1 1 )
 (3)
where λ is the mixing parameter. We used the likelihood ratio with 1 
degree-of-freedom to test the multiplicative (λ = 1) or additive (λ = 0) 
form relative to equation 3 and a profile likelihood to determine the 
95% confidence interval (CI) for λ.
A second approach used a “full” interaction model. For categori-
cal x, we fitted different smoking-related parameters for RR f d n y( , , )  
at each of F levels of x,
 RR RR RRd n y x d n y xf f, , , , ,( ) = + ( ) −  ×{ } ( )∑1 1  (4)
where RR f d n y( , , ) = 1 for d = 0 or x not at level f, and used a likeli-
hood ratio to test multiplicative and additive forms, since equation 4 
embedded each. Our previous analysis found that the RRs for pack-
years relative to never smokers increased linearly, but only within 
categories of cigarettes/day36 (Supplementary Material). This led to 
a two-parameter model for the RR of CVD in pack-years (d) and 
cigarettes/day (n), which we augmented to incorporate years since 
last smoked (y) in categories (<1, 1–9 and ≥10 years). We fitted:
  RR g h( , , ) ( )d n y d n y= + ( )1 β  
where g ln( ) { ( )}n exp n n= =γ γ  and where h expy y
j j j
( ) = ( )∑ θ  with 
yj an indicator variable for category j and exp( )θ j  represented the 
time since cessation effect on the strength of the pack-years associa-
tion, with θ1 0=  for identifiability. At n cigarettes/day, β g(n) was the 
linear slope, that is, the ERR per pack-year, which represented the 
strength of association. For factor x, we used the exponential form, 
RR exp( )x x
f f f
= ( )∑ ϕ , with ϕ1 = 0 for identifiability.
Inference was similar for equations 3 or 4.  Using the Akaike 
Information Criterion (AIC),45 equation 3 was preferred over equa-
tion 4 for all variables, except hypertension where the AIC was mini-
mally larger. We therefore presented results for equation 3 in the 
main text and for both approaches in Supplementary Material. For 
a categorical effect modifier, the value of the mixing parameter (λ) 
depended on referent level. However, for the full model, equation 4, 
deviances for multiplicative (λ = 1) and additive (λ = 0) models did 
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not depend on referent level, suggesting the choice of referent did not 
affect inference for these signpost models.
For the additive, multiplicative, full and geometric mixture mod-
els, equations 1–4, respectively, we designated the minimum AIC as 
the preferred model. However, a preferred model did not imply that 
other models were statistically inconsistent with the data. If neither 
the additive nor the multiplicative model was rejected (or nearly 
rejected) relative to equation 3, then we designated the joint associa-
tion as “indeterminate.” Finally, we adapted the RR functions for a 
continuous modifier x and presented results in Supplementary Tables 
S4 and S5.
We used the Epicure software for analyses.46
Models adjusted for study site, sex, birth year, race, BMI, edu-
cational level, gm-ethanol/wk (never and tertiles based on cases), 
hypertensive status, diagnosed DM, TC and an indicator variable for 
cigar/pipe use in never-cigarette smokers. We adjusted for attained 
age with four variables, continuous age and its natural logarithm 
separately for males and females. For lipid-related variables, we 
replaced TC with the variable under consideration. For complete-
ness, Supplementary Table S1 provides descriptive statistics for 
selected adjustment variables (site, sex, race, birth year, education 
and alcohol use).
Results
Joint RRs for Pack-Years and Cigarettes/Day
RRs increased linearly with pack-years within categories of ciga-
rettes/day (Figure 1, upper panels). Slope estimates of the ERR/pack-
year were 0.030, 0.023, 0.017 and 0.011 for categories 1–19, 20–29, 
30–39 and ≥40 cigarettes/day, respectively, exhibiting a decreasing 
strength of association with increasing cigarettes/day (p < .01 for the 
test of γ = 0 in equation 5). Figure 1 (lower panel), with additional 
categories, shows the inverse pattern across the full range of ciga-
rettes/day. As a result, for equal pack-years smoking fewer cigarettes/
day for longer duration was more deleterious than smoking more 
cigarettes/day for shorter duration. For example, for 50 pack-years 
(≈365 000 cigarettes), estimated RRs of CVD using 20 cigarettes/day 
for 50 years or 30 cigarettes/day for 33.3 years or 50 cigarettes/day 
for 20 years were 2.1, 1.9 and 1.6, respectively. These values differed 
slightly from earlier results36 due to the censoring restriction.
Effect Modification: Smoking and Non-tobacco Risk 
Factors
As expected, RRs increased significantly with hypertension, BMI, 
WHR, DM, and levels of glucose and insulin (Table 1). After adjust-
ment for non-tobacco risk factors (see footnote a), within categories 
of each risk factor, RR trends with pack-years generally increased, 
with trends diminishing at higher categories, suggestive of a sub-
multiplicative association. Note that the apparent steeper trend in 
normotensives resulted from the difference between never and ever 
smokers; among smokers RR trends by pack-years were similar. 
Using equation 5, the estimated ERR/pack-year at 20 cigarettes/day 
was similar by hypertensive status, and generally declined for the 
other factors, reflecting reduced strengths of association. The joint 
association of smoking and hypertension was consistent with a 
multiplicative model and rejected an additive. Joint associations for 
BMI, WHR, DM, glucose and insulin were consistent with additive 
(non-synergistic) relationships, and rejected or nearly rejected (for 
BMI and WHR) multiplicative associations.
RRs increased significantly with TC, TRIG, apoB, LDL, and TC/
HDL. Within each category, RR trends increased with pack-years 
(Table  2). The fitted estimates of ERR/pack-year at 20 cigarettes/
day were similar across levels, suggesting comparable trends with 
pack-years (Table 2) and a multiplicative joint association. Formally, 
hypothesis tests rejected additive models for smoking and TC, apoB, 
LDL, and TC/HDL. The smoking and TRIG association was inde-
terminate, that is, consistent with both multiplicative and additive 
relationships.
RRs decreased significantly with apoA-I, HDL, HDL(2) and 
HDL(3). For apoA-I and cigarette smoking, the joint association was 
consistent with additive (p = .43) and multiplicative forms (p = .31) 
and thus indeterminate. For HDL and HDL(2), the associations 
were consistent with additive models and nearly rejected (p = .09) 
or rejected (p < .01) multiplicative models, respectively. For HDL(3) 
and smoking, a multiplicative model was consistent, while an addi-
tive association was rejected.
We provided additional results in Supplementary Tables S2–S5 
and graphical representations in Supplementary Figures S1–S15.
Discussion
Cigarette smoking, hypertension and various metabolic and lipid-
related factors are well-recognized CVD risk factors.1–4 Analyses of 
joint effects of smoking and non-tobacco factors are complicated 
by smoking affecting many of these factors.5–14 The purpose of our 
analysis was to overcome previous limitations of assessments of 
interaction, namely, use of an incomplete characterization of the 
smoking and CVD relationship, resulting in residual confounding 
and uncertain interpretations.
Previous Analyses of Smoking and Non-tobacco Risk 
Factors
The most consistent finding for joint RRs for smoking and non-
tobacco risk factors has been a multiplicative association for smok-
ing status and blood pressure (defined through either systolic blood 
pressure or use of antihypertensive drugs) from observational studies 
in Sweden,30 in Chinese men and women,18,47 and in the EPOCH-
JAPAN study of 10 cohorts,29 as well as one of its constituent stud-
ies.24 A meta-analysis of randomized clinical trials of blood pressure 
lowering drugs observed a similar proportional reduction in CVD 
risk per 5 mmHg lowering of systolic blood pressure across strata 
defined by baseline 5-year predicted CVD risk, where the prediction 
equation included current smoking and other factors.48 These pat-
terns suggested a synergistic relationship, in particular multiplicative 
joint effects, consistent with our findings.
Results from analyses of interactions of smoking and metabolic 
factors have varied. Studies reported RRs for BMI were similar by 
smoking status or levels of cigarettes/day,17,24,30,32 suggestive of a 
multiplicative association, while others reported RRs for BMI were 
greater in nonsmokers,49–51 suggestive of a sub-multiplicative asso-
ciation. A  Finnish study reported RRs for WHR were similar by 
smoking status.52 RRs for diabetes were similar by smoking status 
in a Japanese cohort study,24 while RRs for increased glucose were 
greater in smokers.32 Because small numbers often limit individual 
studies, pooled or meta-analyses are typically the most informa-
tive. In a meta-analysis of 38 cohorts from the Asia-Pacific region, 
estimates of RR per unit BMI were significantly greater in current 
smokers than in non-smokers,16 suggestive of a supra-multiplicative 
association. For diabetes, a meta-analysis of 102 European studies 
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found that the RR was greater in nonsmokers than in smokers,20 
suggestive of a sub-multiplicative/supra-additive association.
Studies have also examined joint RRs for smoking and lipid-
related factors. Analyses of ARIC data with follow-up through 2002 
and 932 CHD events and of the MRFIT study with 428 CHD events 
reported RRs for smoking and LDL were consistent with multiplica-
tive joint associations.21,32 For smoking and TC, RRs were reported 
consistent with multiplicative23,26,27 and supra-multiplicative asso-
ciations.24,25 There have been several pooled and meta-analyses of 
smoking and lipid-related variables.15 In both the EPOCH-JAPAN 
pooling29 and a meta-analysis of 61 western European and North 
American cohorts,31 RRs by TC did not differ by smoking status, 
concordant with our multiplicative joint association. A meta-analy-
sis of 34 cohort studies from the Asia-Pacific region found that the 
RR per unit increase in TC and unit decrease in HDL were signifi-
cantly greater in current smokers than in nonsmokers,28 suggesting 
supra-multiplicative joint associations; however, a companion analy-
sis using categories for TC and for HDL suggested homogeneity by 
Figure 1. Joint relative risk (RR) of cardiovascular disease for categories of pack-years (solid symbol) and cigarettes/day relative to never-smokers and fitted 
linear models (solid line) (upper panels). Lower panel shows estimated excess relative risk per pack-year (ERR/PKY) for cigarettes/day categories (solid symbol), 
with <20 further split into 1–4, 5–9, 10–19 cigarettes/day, and fitted models for continuous pack-years and cigarettes/day (n) with pointwise 95% confidence 
interval (CI) (solid line with shaded area for two-parameter model, and dash line with light dash line for 3-parameter model) (Supplementary Material).
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smoking status. Thus, results for smoking by LDL and by TC, but 
not by HDL, were in general agreement with our findings.
Current Analyses of Smoking and Non-tobacco Risk 
Factors
The varied results reported to date make definitive interpretations 
difficult. Differences may have arisen from the diverse populations, 
small numbers of CVD events in individual studies or residual 
confounding from the use of smoking status or broad categories 
of cigarettes/day, metrics that do not fully characterized smoking 
risk. Our analysis represents the first systematic evaluation to apply 
a comprehensive model for the relationship of smoking and vari-
ous non-tobacco risk factors to examine synergistic/non-synergistic 
associations.36 Results revealed consistency of a multiplicative asso-
ciation for smoking and hypertension, additive (non-synergistic) 
associations for smoking and BMI, WHR, DM, glucose and insulin 
levels (Table 3). Tests rejected multiplicative forms for DM, glucose 
and insulin, while results for BMI and WHR were less definitive. 
Notably, these variables had only modest positive correlations. In 
current smokers, Pearson correlation coefficients were ρ = 0.49 for 
BMI and WHR, ρ = 0.29 for glucose and insulin and ρ ≤ 0.20 for 
others (Supplementary Table S6).
Table 1. Joint Relative Risk (RR) of Cardiovascular Disease (CVD) for High Blood Pressure, Body Mass Index (BMI), Waist to Hip Ratio, 
Previously Diagnosed Diabetes Mellitus (DM), Glucose and Insulin and Pack-years, and the Estimated Excess Relative Risk per Pack-year 
(ERR/PKY) at 20 Cigarettes/Day (CPD)a
Joint RRs of pack-years and modifier Summary of fitted model
RR by pack-years ERR/PKY @ 20 CPDd
Modifier Cases Person-years RRb 0c 1–19 20–29 30–39 40–49 50+ Est 95% CI pMult
e pAdd
None 2857 207686.0 1 1.52 1.82 2.07 2.11 2.17 0.022 (0.018, 0.027)
Hypertension
 No 1414 141115.0 1 1 1.81 1.93 2.39 2.38 2.33 0.024 (0.018, 0.031) .29 .02
 Yes 1443 66570.4 2.04 1 1.28 1.73 1.79 1.87 2.03 0.020 (0.015, 0.027)
BMIf
 <25 683 69204.9 1 1 1.45 2.24 2.47 2.36 2.33 0.028 (0.020, 0.039) .08 .61
 25–29 1221 82134.8 1.28 1 1.41 1.82 1.93 1.90 2.18 0.019 (0.014, 0.027)
 30–34 646 37451.4 1.33 1 1.64 1.64 1.96 2.35 1.89 0.022 (0.014, 0.033)
 ≥35 307 18894.5 1.44 1 1.71 1.18 1.83 1.58 2.34 0.018 (0.008, 0.038)
Waist to hip ratiog
 I 329 49091.4 1 1 1.29 2.01 2.63 2.48 2.02 0.031 (0.019, 0.049) .09 .77
 II 1248 97518.5 1.25 1 1.42 1.85 1.93 2.07 2.11 0.021 (0.015, 0.028)
 III 1280 61075.7 1.40 1 1.62 1.65 1.98 1.96 2.10 0.019 (0.014, 0.026)
DM
 No 2196 188988.9 1 1 1.55 2.00 2.23 2.30 2.31 0.026 (0.021, 0.032) <.01 .99
 Yes 687 20310.4 2.57 1 1.45 1.33 1.62 1.52 1.74 0.010 (0.005, 0.020)
Glucose (mmol/L)
 <5.6 1229 119622.3 1 1 1.61 2.05 2.29 2.37 2.31 0.027 (0.020, 0.035) <.01 .13
 5.6–6.9 1062 73079.5 1.12 1 1.44 1.81 2.07 2.07 2.24 0.023 (0.017, 0.032)
 ≥7.0 592 16597.2 1.55 1 1.47 1.39 1.63 1.61 1.71 0.011 (0.006, 0.022)
Insulin (pmol/L)
 <60 905 93999.3 1 1 1.45 2.32 2.52 2.30 2.32 0.029 (0.021, 0.038) .02 .63
 60–104 878 64154.5 1.22 1 1.47 1.90 1.98 2.16 2.10 0.016 (0.003, 0.090)
 ≥105 1100 51145.1 1.56 1 1.65 1.38 1.78 1.87 2.02 0.017 (0.011, 0.026)
CI = confidence interval. Data from the Atherosclerosis Risk in Communities Study.
aModels adjusted for center, birth year, age, sex, race, education, current alcohol consumption, previous diagnosis of high blood pressure, previous diagnosis of DM, 
total cholesterol, BMI, use of cigars or pipe exclusively, and cessation of smoking. RRs based on the cross-classification of pack-years and levels of the factor, and 
reflect current smokers. The RR trend for each modification variable was statistically significant, p < .05. Numbers of events and person-years vary due to missing 
data. For all data, numbers of CVD cases for pack-years categories were 1094 (never-smoker), 536, 267, 279, 253 and 428, respectively.
bRRs in relation to the referent category, denoted “1”, and never-smokers with all trends significant.
cReferent category of never-smokers within each level of modification variable.
dFor continuous pack-years (d) and cigarettes/day (n) with categorical modifying factor xf, data fitted using the “full” model,
RR ex ln exp exp( , , , ) ( )d n y x d n y x
f f f f f j j j f f
= + { } ( )  ×∑ ∑ ∑1 β γ θ ϕ f( ) .
with fitted ERR/PKY estimate at 20 cigarettes/day computed as ERR y exp ln( , , , ) { ( )}d n y xf f f= = = =1 20 201 β γ  and where yj represents indicator variables for 
categories of years since last smoked with exp( )θ j  the effect with θ1 set to 0 for identifiability for current smokers.
ep values, pMult, and pAdd, for test of consistency of a multiplicative (λ = 1) or additive (λ = 0) model, respectively, for the joint association of smoking and categories 
of the modification variable, xf, using the geometric mean mixture model.
RR d g exp exp d g( , , , ) ( ) (d n y x n y x n
j j j f f f
= + ( ){ } × ( )  ×∑ ∑1 β θ ϕ βλ ) ( )ex exp∑ ∑( ) + ( )  −j j j f f fy xθ ϕ λ1
fBMI, body mass index.
gCategories for waste to hip ratio: I, ≤0.90 for males and ≤0.85 for females; II and III, category cut-point defined by median of CVD cases, 0.98 for males and 
0.95 for females.
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Table 2. Joint Relative Risk (RR) of Cardiovascular Disease (CVD) by Pack-years With Never Cigarette Smokers as Referent, Model 
Parameter Estimates and the Fitted Excess Relative Risk per Pack-year (ERR/PKY) at 20 Cigarettes/Day (CPD) for Levels of Lipid 
Biomarkersa
Joint RRs of pack-years and modifier Summary of fitted model
RR by pack-years ERR/PKY @ 20 CPDd
Modifier Cases Person-years RRb 0c 1–19 20–29 30–39 40–49 50+ Est 95% CI pMult
e pAdd
Total cholesterol (mmol/L)
 <5.20 894 82420.1 1 1 1.55 2.06 2.02 1.99 2.11 0.024 (0.017, 0.033) .52 <.01
 5.20–6.19 1020 73573.2 1.26 1 1.49 1.79 1.89 2.28 2.08 0.020 (0.014, 0.029)
 ≥6.20 866 49125.7 1.47 1 1.56 1.80 2.54 2.11 2.51 0.026 (0.019, 0.036)
Triglycerides (mg/dL)
 <1.70 1768 154441.0 1 1 1.46 1.93 2.20 2.08 2.02 0.022 (0.017, 0.029) .98 .20
 1.70–2.29 505 29273.0 1.12 1 1.75 1.78 1.72 2.12 2.51 0.023 (0.015, 0.036)
 ≥2.30 507 21404.9 1.32 1 1.47 1.66 1.97 2.14 2.23 0.021 (0.013, 0.034)
Apolipoprotein B (mg/L)
 <870 926 96347.2 1 1 1.51 1.70 2.04 2.15 2.06 0.023 (0.016, 0.032) .81 .02
 870–1119 896 62392.4 1.20 1 1.63 2.12 2.02 2.21 2.31 0.023 (0.017, 0.032)
 ≥1120 958 46379.4 1.63 1 1.38 1.75 2.05 1.90 2.13 0.020 (0.014, 0.029)
LDL (mmol/L)
 <2.6 295 34492.8 1 1 1.54 1.78 1.57 1.80 1.94 0.022 (0.012, 0.038) .99 <.01
 2.6–3.3 681 62200.5 1.13 1 1.46 1.85 2.11 2.26 2.27 0.022 (0.015, 0.033)
 3.4–4.0 781 55205.4 1.28 1 1.66 2.03 2.10 2.27 2.06 0.025 (0.018, 0.036)
 ≥4.1 1023 53220.3 1.73 1 1.44 1.78 2.19 1.98 2.33 0.021 (0.015, 0.030)
Total cholesterol/HDL
 <4.0 695 92729.7 1 1 1.51 1.69 1.95 2.16 2.05 0.023 (0.016, 0.033) .47 .01
 4.0–4.9 638 47730.6 1.43 1 1.19 1.97 1.77 1.94 2.10 0.019 (0.012, 0.030)
 5.0–5.9 607 33090.6 1.75 1 1.44 1.73 1.91 1.93 1.76 0.015 (0.009, 0.025)
 ≥6.0 840 31568.0 2.07 1 1.65 1.63 2.03 1.94 2.17 0.021 (0.014, 0.030)
Apolipoprotein A-I (mg/L)
 <1100 879 42835.2 1 1 1.47 1.84 1.96 1.88 2.14 0.020 (0.014, 0.029) .31 .43
 1100–1329 935 62222.4 0.86 1 1.62 2.03 1.88 1.95 1.84 0.019 (0.013, 0.028)
 ≥1330 966 100061.0 0.70 1 1.37 1.55 2.20 2.34 2.37 0.024 (0.017, 0.033)
HDL (mmol/L)
 <1.00 988 42092.0 1 1 1.60 1.59 1.87 1.87 1.96 0.017 (0.011, 0.025) .09 .29
 1.00–1.29 941 62497.2 0.84 1 1.34 1.94 1.66 1.82 2.00 0.018 (0.013, 0.027)
 1.30–1.59 513 47676.1 0.66 1 1.41 1.85 2.47 2.27 2.28 0.026 (0.017, 0.039)
 ≥1.60 338 52853.7 0.50 1 1.44 1.46 2.29 2.45 2.25 0.026 (0.016, 0.043)
HDL(2) (mmol/L)
 <0.21 866 44220.8 1 1 1.59 1.68 1.99 1.74 2.25 0.018 (0.012, 0.027) <.01 .18
 0.21–0.33 977 60082.2 1.01 1 1.31 1.64 1.67 2.06 1.68 0.016 (0.011, 0.024)
 ≥0.34 937 100816.0 0.68 1 1.59 2.15 2.54 2.42 2.60 0.032 (0.024, 0.042)
HDL(3) (mmol/L)
 <0.74 861 36522.3 1 1 1.55 1.67 1.95 2.16 2.13 0.022 (0.015, 0.031) .67 .05
 0.74–0.95 951 61022.4 0.87 1 1.44 1.99 1.76 1.58 1.98 0.015 (0.010, 0.023)
 ≥0.96 968 107574.0 0.62 1 1.41 1.56 2.13 2.31 2.05 0.023 (0.016, 0.032)
CI = confidence interval; HDL = high density lipoproteins; LDL = low density lipoproteins. Data from the Atherosclerosis Risk in Communities Study.
aModels adjusted for center, birth year, age, sex, race, education, current alcohol consumption, previous diagnosis of high blood pressure, previous diagnosis of 
diabetes mellitus, body mass index (BMI) and use of cigars or pipe exclusively, and cessation of smoking and the modification factor. RRs based on the cross-
classification of pack-years and levels of the factor, and reflect current smokers. The RR trend for each modification variable was statistically significant, p < .05. 
Numbers of events and person-years vary due to missing data. For all data, numbers of CVD cases for pack-years categories were 1094 (never-smoker), 536, 267, 
279, 253, and 428, respectively.
bRRs in relation to the referent category, denoted “1”, and never-smokers, with all trends significant.
cReferent category of never-smokers within each level of modification variable.
dFor continuous pack-years (d) and cigarettes/day (n) with categorical modifying factor xf, data fitted using the “full” model,
RR exp ln exp exp ( , , , ) { ( )}d n y x d n y
f f f f f j j j f
= + ∑ ∑ × ∑( ) 1 β γ θ ϕ f fx( ).
with fitted ERR/PKY estimate at 20 cigarettes/day computed as ERR exp ln( , , , ) { ( )}d n y y xf f f= = = =1 20 1 20β γ and where yj represents indicator variables for 
categories of years since last smoked with exp( )θ j  the effect with θ1 set to 0 for identifiability for current smokers.
ep values, pMult, and pAdd, for test of consistency of a multiplicative (λ = 1) or additive (λ = 0) model, respectively, for the joint association of smoking and categories 
of the modification variable, xf, using the geometric mean mixture model.
RR d g exp exp d g( , , , ) ( ) (d n y x n y x n
j j j f f f
= + ( ){ } × ( )  ×∑ ∑1 β θ ϕ βλ ) ( )exp exp∑ ∑( ) + ( )  −j j j f f fy xθ ϕ λ1
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Among lipid-related factors, joint RRs were consistent with multi-
plicative (synergistic) associations for smoking and TC, apoB, LDL and 
TC/HDL While correlations for TC and LDL (ρ = 0.92) and for LDL 
and apoB (ρ = 0.74) were high, other correlations for these variables 
were lower (Supplementary Table S6). While correlation coefficients for 
apoA-I, HDL, HDL(2) and HDL(3) were 0.49 and higher, interactions 
of smoking and HDL-related factors varied. The joint RRs for smoking 
and HDL and HDL(2) were consistent with additive (non-synergistic) 
associations,, while the joint association for smoking and HDL(3) was 
consistent with a multiplicative association. Joint associations for smok-
ing and TRIG and for smoking and apoA-I were indeterminate.
Physiologic Evidence for Joint Associations
Smoking affects CVD risk through several mechanisms, includ-
ing endothelial dysfunction, platelet activation, increased oxidative 
stress, increased inflammation and modification of lipid profiles.53–56 
Meanwhile, mechanisms that associate diabetes-related factors with 
accelerated atherosclerosis and increased CVD risk likely involve 
insulin resistance and chronic hyperglycemia.57,58 This suggests dis-
tinct pathways, which generally conform to our observation of non-
synergistic associations. The multiplicative association for smoking 
and TC and LDL-related factors may result from actions at different 
points within a common CVD-related process, where for example, TC 
and LDL influence plaque initiation (earlier atherosclerotic-related 
events) and smoking modifies plaque progression (advanced athero-
sclerotic-related events),15,59 as well as plaque stability.14 This suggests 
that smoking may have a greater impact instigating acute coronary 
events than on general atherogenesis.53 In contrast, the additive asso-
ciation for HDL-related variables may derive from smoking directly 
influencing HDL levels and the integrity of its effects. Smoking impacts 
various stages of HDL metabolism, including HDL biosynthesis and 
maturation, intravascular remodeling of HDL and HDL catabolism.55 
A reduction of HDL may attenuate its functionality and anti-athero-
genic effects, for example, reducing reverse cholesterol transport and 
hepatic uptake,55 and its anti-oxidant, anti-inflammatory and anti-
thrombotic effects.60 In addition, smoking mainly reduces HDL(2), 
while affecting little change in HDL(3),55 suggesting distinct roles for 
smoking relative to HDL(2) and HDL(3), which was consistent with 
our diverse results for HDL and its sub-fractions.
Limitations
These analyses have several limitations. Results are from a single 
study and therefore warrant cautious interpretation pending con-
firmatory analyses. Although we censored participants at change in 
smoking status, we used non-tobacco variables that were ascertained 
at enrollment, while pack-years and years since smoking cessation 
incorporated time-dependent changes. This distinction is important 
since potential mechanisms of action for CVD risk from hyperten-
sion, metabolic and lipid-related variables can have both acute and 
chronic components.1,2,14,53 It would therefore worthwhile for future 
analyses to incorporate time-dependent measurements of non-
tobacco risk factors. In addition, the fitted models reflected observed 
Table 3. Summary of Results for Modelsa of the Evaluation of Synergistic/Non-synergistic Relationships for the Joint Association of 
Cigarettes Smoking and Non-tobacco Risk Factors for Cardiovascular Disease
Tests of joint association with 
smokingb Geometric mixturec
Modifying factor Multiplicative Additive λ 95% CI AIC d pe
Hypertension Accept Reject 0.6 (0.1,1.4) Multiplicative .02 (A)
BMI Accept Accept −0.3 (−1.1,1.3) Additive .08 (M)
Waist to hip ratio Accept Accept −0.1 (−0.9,1.2) Additive .09 (M)
Diabetes mellitus Reject Accept 0.0 (−0.3,0.5) Additive <.01 (M)
Glucose Reject Accept −0.8 (−2.5,0.2) GMIX f <.01 (M)
Insulin Reject Accept −0.2 (−0.7,0.7) Additive .02 (M)
Total cholesterol Accept Reject 1.4 (0.4, 3.7) Multiplicative <.01 (A)
Triglycerides Accept Accept 0.9 (−0.3, 4.3) Multiplicative g .98 (M), .20 (A)
Apolipoprotein B Accept Reject 0.9 (0.1, 2.2) Multiplicative .02 (A)
LDL Accept Reject 1.0 (0.3, 2.5) Multiplicative <.01 (A)
Total cholesterol/HDL Accept Reject 0.7 (0.2, 1.6) Multiplicative .01 (A)
Apolipoprotein A-I Accept Accept 0.4 (−0.6, 1.6) Additive g 0.31 (M), .43 (A)
HDL Accept Accept 0.4 (−0.5, 0.8) Additive .09 (M)
HDL(2) Reject Accept −0.6 (−1.6, 0.3) Additive <.01 (M)
HDL(3) Accept Reject 0.8 (0.1, 1.7) Multiplicative .05 (A)
AIC = Akaike Information Criterion; BMI = body mass index; CI = confidence interval; HDL = high density lipoproteins; LDL = low density lipoproteins.
aResults for tests of consistency of a multiplicative (λ = 1) or additive (λ = 0) model, respectively, using a geometric mixture model for the joint association of smok-
ing and categories of the modification variable (equation 3). Summary of model results from Supplementary Tables S1 and S2.
bp value for the 1-degree of freedom test of an multiplicative or additive model in relation to a geometric mixture model, with “Accept” denoting p > .05 and 
“Reject” denoting p ≤ .05.
cMaximum likelihood estimate and likelihood-based 95% CI for the mixing parameter in a geometric mixture model (equation 3), where λ = 1 and λ = 0 define 
multiplicative and additive models, respectively.
dPreferred model based on the AIC comparing the full (FULL) (equation 4), geometric mixture (GMIX) (equation 3), multiplicative and additive models (see foot-
notes Tables 1 and 2), with smaller AIC values favored. Designation as a preferred model does not imply statistical rejection of alternative models.
eFor the geometric mixture model with multiplicative (M) and additive (A) relationships as signpost models, p value provides test of rejection of the alternative 
signpost relationship, shown in parentheses. If likelihood ratio tests failed or nearly failed to reject both null hypotheses (λ = 0 and λ = 1), we designated the assess-
ment of signpost models as indeterminate.
fWhile the geometric mixture model (AIC = −6.0) was preferred, the additive model (AIC = −5.7) had similar AIC.
gDesignated indeterminate, since tests did not reject either signpost model relative to the geometric mixture model.
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RR patterns using imprecise exposures, which may affect our assess-
ment of multiplicative and additive forms, themselves merely sign-
post models on a continuum ranging from sub-additive through 
supra-multiplicative. Furthermore, implications of these models 
in relation to specific cellular and molecular disease processes are 
unclear. Nonetheless, the consistency of the observed RR patterns 
for related variables suggested that results may have expressed 
underlying processes and highlighted their potential utility for evalu-
ating public health effects and improving risk prediction.
Additional concern is that competing risks possibly affected our 
observed RR patterns for smoking, whereby participants with longer 
follow-up or lower smoking rate may have increased likelihood of 
incurring CVD events, while heavier smokers were selectively removed 
from follow-up due to other diseases. We carried out a competing risk 
analysis that accounted for smoking-related cancers and found no 
appreciable difference in results, suggesting minimal impact.
Conclusions
Analysis revealed distinct RR patterns for cigarette smoking and non-
tobacco factors, including synergistic/multiplicative (hypertension, TC, 
LDL, apoB, TC/HDL, HDL(3)), non-synergistic/additive (BMI, WHR, 
DM, glucose, insulin, HDL, HDL(2)) and indeterminate (apoA-I and 
TRIG) associations; however, confirmatory analyses are needed. An 
improved understanding of joint associations among CVD risk factors 
can clarify the public health burden of smoking on CVD, causal links 
between etiologic factors and biologic mechanisms, where synergistic 
associations highlight joint impacts and non-synergistic associations 
suggest distinct contributions from each factor.
Supplementary Material
Supplementary Table S1–S6 and Figures S1–S15 can be found online 
at http://www.ntr.oxfordjournals.org
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